FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1753260079> ?p ?o ?g. }

• W1753260079 endingPage "11675" @default.
• W1753260079 startingPage "11664" @default.
• W1753260079 abstract "// Emeline Tabouret 1, 2 , Aurelie Tchoghandjian 1 , Emilie Denicolai 1 , Christine Delfino 1 , Philippe Metellus 1, 3 , Thomas Graillon 1, 3 , Celine Boucard 2 , Isabelle Nanni 4 , Laetitia Padovani 5 , L’Houcine Ouafik 1, 4 , Dominique Figarella-Branger 1, 6 , Olivier Chinot 1, 2 1 Aix-Marseille Univ, CRO2, UMR 911, Marseille 13284, France 2 APHM, Timone Hospital, Department of Neuro-Oncology, Marseille 13005, France 3 APHM, Timone Hospital, Department of Neuro-Surgery, Marseille 13005, France 4 APHM, North Hospital, Transfer Laboratory, Marseille 13015, France 5 APHM, Timone Hospital, Department of Radiotherapy, Marseille 13005, France 6 APHM, Timone Hospital, Department of Anatomopathology, Marseille 13005, France Correspondence to: Olivier Chinot, e-mail: olivier.chinot@ap-hm.fr Keywords: Angiogenesis, glioblastoma, paired, switch Received: December 14, 2014      Accepted: January 29, 2015      Published: March 25, 2015 ABSTRACT Angiogenesis is one of the key features of glioblastoma (GBM). Our objective was to explore the potential changes of angiogenic factors in GBM between initial diagnosis and recurrence after radiotherapy-temozolomide (RT/TMZ). Paired frozen tumors from both initial and recurrent surgery were available for 29 patients. Screening of genes expressions related to angiogenesis was performed using RT- PCR arrays on 10 first patients. Next, RNA expressions of the selected genes were analyzed on all samples. Protein expression was examined by immunohistochemistry. The anti-tumor effect of AMD3100 (anti-CXCR4) was tested in GBM explants. In the screening step, the initial-recurrence expression changes contributed to a selection of seven genes ( VEGFA, VEGFR2, VEGFR1, CXCL12, CXCR4, uPA HIF1α). By quantitative RT-PCR, RNA expressions of CXCR4 ( p = 0.029) and CXCL12 ( p = 0.107) were increased while expressions of HIF1α ( p = 0.009) and VEGFR2 ( p = 0.081) were decreased at recurrence. Similarly, CXCL12 protein expression tended to increase ( p = 0.096) while VEGFR2 staining was decreased ( p = 0.004) at recurrence. An increase of anti-tumoral effect was observed with the combination of AMD3100 and RT/TMZ versus RT/TMZ alone in GB explants. Recurrence of GB after chemo-radiation could be associated with a switch of angiogenic pattern from VEGFR2-HIF1α to CXCL12-CXCR4 pathway, leading to new perspectives in angiogenic treatment." @default.
• W1753260079 created "2016-06-24" @default.
• W1753260079 creator A5000418022 @default.
• W1753260079 creator A5011908068 @default.
• W1753260079 creator A5029963139 @default.
• W1753260079 creator A5032247621 @default.
• W1753260079 creator A5040619594 @default.
• W1753260079 creator A5045881672 @default.
• W1753260079 creator A5047191938 @default.
• W1753260079 creator A5059620448 @default.
• W1753260079 creator A5075387803 @default.
• W1753260079 creator A5085851934 @default.
• W1753260079 creator A5088340421 @default.
• W1753260079 creator A5066316508 @default.
• W1753260079 date "2015-03-25" @default.
• W1753260079 modified "2023-10-17" @default.
• W1753260079 title "Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway" @default.
• W1753260079 cites W1587922612 @default.
• W1753260079 cites W1629179716 @default.
• W1753260079 cites W1696199194 @default.
• W1753260079 cites W1969328947 @default.
• W1753260079 cites W1975104842 @default.
• W1753260079 cites W1977123185 @default.
• W1753260079 cites W1979975126 @default.
• W1753260079 cites W1980275866 @default.
• W1753260079 cites W1988011020 @default.
• W1753260079 cites W1992112921 @default.
• W1753260079 cites W2001009247 @default.
• W1753260079 cites W2020021293 @default.
• W1753260079 cites W2022109171 @default.
• W1753260079 cites W2027572371 @default.
• W1753260079 cites W2027853858 @default.
• W1753260079 cites W2044792043 @default.
• W1753260079 cites W2046220184 @default.
• W1753260079 cites W2073477133 @default.
• W1753260079 cites W2075760429 @default.
• W1753260079 cites W2096287682 @default.
• W1753260079 cites W2096800614 @default.
• W1753260079 cites W2100825620 @default.
• W1753260079 cites W2106402868 @default.
• W1753260079 cites W2108244474 @default.
• W1753260079 cites W2114098415 @default.
• W1753260079 cites W2118731052 @default.
• W1753260079 cites W2119996840 @default.
• W1753260079 cites W2124736921 @default.
• W1753260079 cites W2126000912 @default.
• W1753260079 cites W2127745545 @default.
• W1753260079 cites W2132697290 @default.
• W1753260079 cites W2152474871 @default.
• W1753260079 cites W2156330848 @default.
• W1753260079 cites W2158106887 @default.
• W1753260079 cites W2160382843 @default.
• W1753260079 cites W2161476194 @default.
• W1753260079 cites W2162643152 @default.
• W1753260079 cites W2163175652 @default.
• W1753260079 cites W2163501248 @default.
• W1753260079 cites W2332959603 @default.
• W1753260079 doi "https://doi.org/10.18632/oncotarget.3256" @default.
• W1753260079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4484484" @default.
• W1753260079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25860928" @default.
• W1753260079 hasPublicationYear "2015" @default.
• W1753260079 type Work @default.
• W1753260079 sameAs 1753260079 @default.
• W1753260079 citedByCount "39" @default.
• W1753260079 countsByYear W17532600792015 @default.
• W1753260079 countsByYear W17532600792016 @default.
• W1753260079 countsByYear W17532600792017 @default.
• W1753260079 countsByYear W17532600792018 @default.
• W1753260079 countsByYear W17532600792019 @default.
• W1753260079 countsByYear W17532600792020 @default.
• W1753260079 countsByYear W17532600792021 @default.
• W1753260079 countsByYear W17532600792022 @default.
• W1753260079 countsByYear W17532600792023 @default.
• W1753260079 crossrefType "journal-article" @default.
• W1753260079 hasAuthorship W1753260079A5000418022 @default.
• W1753260079 hasAuthorship W1753260079A5011908068 @default.
• W1753260079 hasAuthorship W1753260079A5029963139 @default.
• W1753260079 hasAuthorship W1753260079A5032247621 @default.
• W1753260079 hasAuthorship W1753260079A5040619594 @default.
• W1753260079 hasAuthorship W1753260079A5045881672 @default.
• W1753260079 hasAuthorship W1753260079A5047191938 @default.
• W1753260079 hasAuthorship W1753260079A5059620448 @default.
• W1753260079 hasAuthorship W1753260079A5066316508 @default.
• W1753260079 hasAuthorship W1753260079A5075387803 @default.
• W1753260079 hasAuthorship W1753260079A5085851934 @default.
• W1753260079 hasAuthorship W1753260079A5088340421 @default.
• W1753260079 hasBestOaLocation W17532600791 @default.
• W1753260079 hasConcept C126322002 @default.
• W1753260079 hasConcept C129470790 @default.
• W1753260079 hasConcept C13373296 @default.
• W1753260079 hasConcept C143998085 @default.
• W1753260079 hasConcept C170493617 @default.
• W1753260079 hasConcept C204232928 @default.
• W1753260079 hasConcept C2776194525 @default.
• W1753260079 hasConcept C2777389519 @default.
• W1753260079 hasConcept C2780394083 @default.
• W1753260079 hasConcept C502942594 @default.
• W1753260079 hasConcept C509974204 @default.

• next